Cyclerion Therapeutics EBITDA Margin Growth & History (CYCN)

Cyclerion Therapeutics's ebitda margin was −239.78% for fiscal 2025.

View full Cyclerion Therapeutics company overview

Cyclerion Therapeutics annual ebitda margin history

Cyclerion Therapeutics annual ebitda margin

Fiscal yearPeriod endedEBITDA marginChange (percentage points)
20252025-12-31−239.78%−58.38 pp
20242024-12-31−181.40%
20222022-12-31−6,220.54%−4832.33 pp
20212021-12-31−1,388.20%+2051.17 pp
20202020-12-31−3,439.37%−725.00 pp
20192019-12-31−2,714.38%

Cyclerion Therapeutics ebitda margin trends

Over the last five fiscal years, Cyclerion Therapeutics's ebitda margin increased from −3,439.37% to −239.78%, a change of +3199.59 percentage points. The latest reported quarter, Q4 2025, shows −81.76%.

About the metric

What EBITDA margin means

EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.

Calculation and source

How EBITDA margin is calculated

TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Cyclerion Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about CYCN yet. Start the conversation.

Write the first post